A randomized, double-blind, placebo-controlled study to evaluate the safety of 12 weeks of dosing with GW856553 and its effects on inflammatory markers, infarct size, and cardiac function in subjects with myocardial infarction without STsegment elevation.

Trial Profile

A randomized, double-blind, placebo-controlled study to evaluate the safety of 12 weeks of dosing with GW856553 and its effects on inflammatory markers, infarct size, and cardiac function in subjects with myocardial infarction without STsegment elevation.

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Dec 2017

At a glance

  • Drugs Losmapimod (Primary)
  • Indications Myocardial infarction
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Acronyms SOLSTICE
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 01 Apr 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 19 Aug 2011 Planned end date changed from 1 Sep 2011 to 1 Apr 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top